Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations i… Read more
Marinus Pharmaceuticals Inc (MRNS) - Total Liabilities
Latest total liabilities as of September 2024: $130.36 Million USD
Based on the latest financial reports, Marinus Pharmaceuticals Inc (MRNS) has total liabilities worth $130.36 Million USD as of September 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Marinus Pharmaceuticals Inc - Total Liabilities Trend (2012–2023)
This chart illustrates how Marinus Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Marinus Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Marinus Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Titania Holding AB Series B
ST:TITA-B
|
Sweden | Skr3.70 Billion |
|
HEALTH NET
F:HNT
|
Germany | €1.45 Billion |
|
LPS Brasil - Consultoria de Imóveis S.A
SA:LPSB3
|
Brazil | R$161.20 Million |
|
Celik Halat ve Tel Sanayi AS
IS:CELHA
|
Turkey | TL2.50 Billion |
|
Metallic Minerals Corp
OTCQB:MMNGF
|
USA | $861.37K |
|
Alto Metals Ltd
AU:AME
|
Australia | AU$999.52K |
|
Cayenne Entertainment Technology Co. Ltd.
TWO:4946
|
Taiwan | NT$110.33 Million |
|
Solid State System Co. Ltd.
TWO:3259
|
Taiwan | NT$193.48 Million |
Liability Composition Analysis (2012–2023)
This chart breaks down Marinus Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.95 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Marinus Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Marinus Pharmaceuticals Inc (2012–2023)
The table below shows the annual total liabilities of Marinus Pharmaceuticals Inc from 2012 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $154.14 Million | +7.40% |
| 2022-12-31 | $143.52 Million | +72.18% |
| 2021-12-31 | $83.35 Million | +528.47% |
| 2020-12-31 | $13.26 Million | +19.78% |
| 2019-12-31 | $11.07 Million | +60.27% |
| 2018-12-31 | $6.91 Million | +159.35% |
| 2017-12-31 | $2.66 Million | -73.27% |
| 2016-12-31 | $9.97 Million | -21.76% |
| 2015-12-31 | $12.74 Million | +40.64% |
| 2014-12-31 | $9.06 Million | +282.92% |
| 2013-12-31 | $2.37 Million | -47.43% |
| 2012-12-31 | $4.50 Million | -- |